Autoantibodies against Desmoglein 1 and 3 in South Tunisian pemphigus
##plugins.themes.academic_pro.article.main##
Abstract
Abstract
Background
Desmoglein (Dsg) 1 and 3 are the 2 major autoantigens in pemphigus foliaceus (PF) and pemphigus vulgaris (PV).
Aim
We aimed to determine anti-Dsg1 and 3 Abs’usefulness in the diagnosis of pemphigus and to assess the correlation of these antibodies (Abs) with clinical phenotype and disease activity in south Tunisian patients.
Methods
We retrospectively analyzed 131 samples from 82 patients (52 with PF and 30 with PV) during follow-up. Anti-Dsg1 and 3 Abs were measured by ELISA. Consecutive anti-Dsg1 and 3 Abs were correlated with disease activity. Receiver operating characteristics (ROC) curve were calculated to determine anti-Dsg1 and 3 Abs’cut-offs with optimal sensitivity and specificity for disease activity.
Results
Anti-Dsg1 and 3 levels were associated to in PF and PV patients respectively (p<0,001). Anti-Dsg1 and 3 Ab were associated with skin (95%) and mucosal (60%) lesions, respectively. A significant decrease of anti-Dsg1 Abs was observed in patients with PF in clinical remission (36 ± 62 U/mL; (p=0,04). No correlation was found between anti-Dsg3 Abs and the course of mucosal lesions in PV (p=0,3). During follow-up, anti-Dsg1 Abs correlated with relapses (177 ±60 U/mL ; p=0,04). The 161,5 U/mL cut-off for anti-Dsg1 Abs provided 100% specificity and 86,4% sensitivity in PF disease activity. The 30,7U/mL cut-off for anti-Dsg3 provided 89,5% sensitivity and 100% specificity in PV.
Conclusions
High anti-Dsg3 Abs values are not always associated with PV disease activity. Anti-Dsg1 Abs showed a closer relationship with skin activity in PS and should be therefore taken into account in management of pemphigus patients.
Keywords:
antibodies, desmglein 1 and 3, pemphigus, South Tunisian, ELISA##plugins.themes.academic_pro.article.details##
References
- (1) Sagi L, Sherer Y, Trau H, Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev 2008;8:33-5. (2) Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011;29:432-6. (3) Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, et al. Comparative epidemiology of pemphigus in Tunisia and France. Incidence of foliaceus pemphigus in young Tunisian women. Ann Dermatol Venereol 1996;123:337-42. (4) Morini JP, Jomaa B, Gorgi Y, Saguem MH, Nouira R, Roujeau JC et al. Pemphigus Foliaceus in Young Women Pemphigus: An Endemic Focus in the Sousse Area of Tunisia. Arch Dermatol 1993;12 :69-73. (5) Jerbi A, Hachicha H, Feki S, Bahloul E, Sellami K, Abida O, et al. Pemphigus herpetiformis in South Tunisia : a clinical expression of pemphigus foliaceus ? Int J Dermatol. 2018;57:1094-101. (6) Masmoudi H, Abida O, Masmoudi A, Turki H. Update on immunogenetics of Tunisian endemic pemphigus foliaceus. J Leukoc Biol. 2018;1-9. (7) Jerbi A, Hachicha H, Bahloul E, Feki S, Sellami K, Abida O, et al. South Tunisian pemphigus patients beyond 60 years: epidemiological profile and evolution. Int J Dermatol. 2019;1-2. (8) Anand V, Khandpur S, Sharma VK, Sharma A. Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris. J Eur Acad Dermatology Venereol 2012;26:1377-83. (9) Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-8. (10) Masmoudi A, Baricault S , Chikrouhou H, Zahaf A, Turki H, Abida O et al. Pemphigus superficiel tunisien avec anticorps antidesmogléine3. Ann Dermatol Venereol 2008;135:68-69. (11) Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001;144:775-80. (12) Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates for indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol 2001;145:178-82. (13) Tampoia M, Giavarina D, Di Giorgio C, Bizzaro N. Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: A systematic review and meta-analysis. Autoimmun Rev 2012;12:121-6. (14) Huang CH, Chen CC, Wang CJ, Chang YT, Liu HN. Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus. J Chin Med Assoc 2007;70:65-70. (15) Gandhi N, Jain S, Kumar M, Choudhary K. Usefulness of desmoglein 1 and 3 in serodiagnosis of pemphigus vulgaris and its correlation with disease activity - ELISA study. J Orofac Sci 2014;6:104. (16) Bellon N, André C, Sbidian E, Ortonne N, Wolkenstein P, Chosidow O, et al. The Value of Anti-Desmoglein Enzyme-Linked Immunosorbent Assay in the Immunological Follow-Up of Pemphigus. Dermatology 2014;229:256-62. (17) Houivet E, Hebert V, Boulard C, Vaillant M, Lehembre SD, Borradori L, et al. Corrélation entre les scores de sévérité clinique ( ABSIS , PDAI , PGA ), la qualité de vie ( DLQI ) et les taux d ' Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015;142:444-5. (18) Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009;145:529-35. (19) Amagai M, Komai A, Hashimoto T, Shirakata Y, Hashimoto K, Yamada T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999;140:351-7. (20) Avgerinou G, Papafragkaki DK, Nasiopoulou A, et al. Correlation of antibodies against desmogleins 1 and 3 with indirect immunofluorescence and disease status in a Greek population with pemphigus vulgaris. J Eur Acad Dermatology Venereol 2013; 27:430-435. (21) Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, et al. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol 2007;21:1319-24. (22) Cozzani E, Di Zenzo G, Riva S, Calabresi V, Sera F, Drosera M, et al. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. Eur J Dermatology 2013;23:40-8. (23) Carew B, Wagner G. Cutaneous pemphigus vulgaris with absence of desmoglein 1 autoantibodies. An example of the extended desmoglein compensation theory. Australas J Dermatol 2014;55:292-5. (24) Patsatsi A, Kyriakou A, Giannakou A, Pavlitou-Tsiontsi A, Lambropoulos A, Sotiriadis D. Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in pemphigus patients measured by Area Index and Intensity Score. Acta Derm Venereol 2014;94:203-6. (25) Barnadas MA, Rubiales MV, Gich I, Gelpà C. Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity. Int J Dermatol 2015;54:1261-8. (26) Daneshpazhooh M, Zafarmand Sedigh V, Balighi K, Hosseini SH, Ramezani A, Kalantari M-S et al. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. J Am Acad Dermatol 2016;74:1160-5. (27) Naseer SY, Seiffert-Sinha K, Sinha A. Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris. Autoimmunity 2014;48:1-11. (28) Kamiya K, Aoyama Y, Shirafuji Y, Hamada T, Morizane S, Fujii K, et al. Detection of antibodies against the non-calcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance. Br J Dermatol 2012;167:252-61. (29) Kamiya K, Aoyama Y, Shirafuji Y, Hamada T, Morizane S, Fujii K, et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci 2013;70:190-5. (30) Daneshpazhooh M, Kamyab K, Kalantari MS, Balighi K, Naraghi ZS, Shamohammadi S, et al. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Clin Exp Dermatol 2014;39:41-7. (31) Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: Anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol. 2009;161:522-7. (32) Abida O, Mahfoudh N, Kammoun A, Gaddour L, Hakim F, Toumi A, et al. Polymorphisms of HLA microsatellite marker in Tunisian pemphigus foliaceus. Hum Immunol. 2013;74:104-9. (33) Abida O, Masmoudi A, Rebaï A, Ben Ayed M, Mahfoudh N, Kallel-Sellami M, et al. The familial feature of Tunisian endemic pemphigus foliaceus. Br J Dermatol. 2009;161:951-3. (34) Kallel Sellami M, Zitouni M, Tombari W, Ben Ayed M, Abida O, Laadhar L, et al. Anti-desmoglein-1 antibodies are prevalent in Tunisian patients with hydatidosis and leishmaniasis. Br J Dermatol. 2007 Mar;156:591-3. (35) Ben Ayed M, Martel P, Zitouni M, Gilbert D, Turki H, Mokni M, et al. Tunisian endemic pemphigus foliaceus is associated with desmoglein 1 gene polymorphism. Genes Immun. 2002;3:378-9. (36) Bastuji-Garin S, Turki H, Mokhtar I, Nouira R, Fazaa B, Jomaa B, et al. Possible relation of tunisian pemphigus with traditional cosmetics: A multicenter case-control study. Am J Epidemiol. 2002;155:249-56. (37) Abida O, Kallel-Sellami M, Joly P, Ben Ayed M, Zitouni M , Masmoudi A, et al. Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia O. J Eur Acad Dermatology Venereol 2009;23:1083-7.